CME/CE

Host: Joyce O'Shaughnessy, MD Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making.

Host: Raymond Townsend, MD Guest: Melissa Magwire, RN, MSN Guest: Michael Weber, MD The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.

Host: Stefan H. Jacobson, MD, PhD Guest: Carlos Narváez Mejía, MD Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in their itching but in their quality of life. Join the experts as they review the newest real-world data and clinical results of difelikefalin presented at ERA.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Host: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Guest: Scott Solomon, MD Guest: Mikhail Kosiborod, MD There are limited therapeutic options for patients with heart failure with mid-range or preserved ejection fraction (HFmrEF/HFpEF). Recently, new data were released on the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists (MRAs) in patients with HFmrEF/HFpEF. What are the outcomes of the FINEARTS-HF trial with finerenone in this patient population, and what do these findings mean for clinical practice? Three cardiologists discuss the topic of novel therapies, with a focus on nonsteroidal MRAs, to improve cardiovascular outcomes in patients with HFmrEF/HFpEF.

Guest: David Wheeler, MB, CHB, MD, FRCP Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the importance of ongoing monitoring and follow-up to ensure optimal management. You don’t want to miss this opportunity to improve your clinical practice and enhance patient outcomes.

Host: Martha Kingman, DNP, FNP-C Guest: Susanne McDevitt, DNP, ACNP-BC This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.